INmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical Progress

Stock Information for INmune Bio Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About INmune Bio Inc.

INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th
INmune Bio Receives R&D Rebates of Approximately $4.6 Million
INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom(TM) Platform
INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom(TM) Platform
INmune Bio's XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and Pain in New Peer-Reviewed Preclinical Study
INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer's Disease at AAIC
INmune Bio Advances CORDStrom(TM) Platform Patent Application in the U.S. Following Favorable International Written Opinion
INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom(TM)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.